journal article·2019-12-04Open access

GAS5, a FoxO1-actived long noncoding RNA, promotes propofol-induced oral squamous cell carcinoma apoptosis by regulating the miR-1297-GSK3β axis

Chengshun Gao, Chunmei Ren, Zhongxi Liu, Li Zhang, Ranran Tang, Xiaojie Li

Abstract

Propofol, an intravenous anaesthetic agent, has been found to exhibit antitumour effects in various kinds of cancer cells. However, the potential roles and regulatory mechanisms of propofol in oral squamous cell carcinoma (OSCC) remain unknown. Herein, we found that propofol inhibits OSCC cell growth and promotes cell apoptosis in a dose- and time-dependent manner. Further mechanistic studies revealed that the long noncoding RNA GAS5 is induced by propofol in OSCC cells. Elevated GAS5 acts as a competing endogenous RNA for miR-1297 and attenuates its inhibitory effect on GSK3β, leading to GSK3β increase and Mcl1 decrease. Additionally, we found that FoxO1 binds to the promoter of GAS5, facilitating its transcription in response to propofol treatment. Thus, these results suggest that propofol exhibits antitumour effects in OSCC cells and that the FoxO1-GAS5-miR-1297-GSK3β axis plays an important role in propofol-induced OSCC cell apoptosis.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cancer-related molecular mechanisms research · MicroRNA in disease regulation · RNA Research and Splicing

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Anesthesiology, the Second Affiliated Hospital & Department of Prosthodontics, College of Stomatology, Dalian Medical University

Nanjing Maternity and Child Health Care Hospital, Women’s Hospital of Nanjing Medical University

Laboratory of Pathogenic Biology, College of Basic Medical Science, Dalian Medical University

Funding

National Natural Science Foundation of China · Liaoning Provincial Natural Science Foundation of China · Central Government Funds for Major Chronic Diseases of China

References (36)

Show source-provided references
1. 10.1007/s12105-017-0795-010.1007/s12105-017-0795-0 ↗
2. 10.3322/caac.2126210.3322/caac.21262 ↗
3. 10.1016/j.oraloncology.2008.06.00210.1016/j.oraloncology.2008.06.002 ↗
4. 10.1016/j.ejphar.2009.01.00710.1016/j.ejphar.2009.01.007 ↗
5. Kim R. Effects of surgery and anesthetic choice on immunosuppression and cancer recurrence. J Transl Med. 2018;16(8):1–13.
6. 10.3892/or.2016.533210.3892/or.2016.5332 ↗
7. 10.3748/wjg.v19.i33.548510.3748/wjg.v19.i33.5485 ↗
8. Wang P, Chen J, Mu LH, et al. Propofol inhibits invasion and enhances paclitaxel- induced apoptosis in ovarian cancer cells through the suppression of the transcription factor slug. Eur Rev Med Pharmacol Sci. 2013;17(13):1722–1729.
9. 10.1590/1414-431x2016579410.1590/1414-431x20165794 ↗
10. 10.1002/jcb.2895210.1002/jcb.28952 ↗
11. 10.1016/j.cell.2009.02.00610.1016/j.cell.2009.02.006 ↗
12. 10.2217/epi.15.5510.2217/epi.15.55 ↗
13. 10.15252/embr.20164366810.15252/embr.201643668 ↗
14. 10.2147/CMAR.S18905210.2147/CMAR.S189052 ↗
15. 10.1186/s13046-019-1034-110.1186/s13046-019-1034-1 ↗
16. Yang X, Zhang D, Liu S, et al. KLF4 suppresses the migration of hepatocellular carcinoma by transcriptionally upregulating monoglyceride lipase. Am J Cancer Res. 2018;8(6):1019–1029.
17. 10.1016/j.jid.2018.01.02310.1016/j.jid.2018.01.023 ↗
18. 10.12659/MSM.91258110.12659/MSM.912581 ↗
19. He W, Yuan QH, Zhou Q. Histamine H3 receptor antagonist clobenpropit protects propofol-induced apoptosis of hippocampal neurons through PI3K/AKT pathway. Eur Rev Med Pharmacol Sci. 2018;22(22):8013–8020.
20. 10.1016/j.febslet.2010.05.06110.1016/j.febslet.2010.05.061 ↗
21. 10.1016/j.molcel.2006.02.00910.1016/j.molcel.2006.02.009 ↗
22. 10.3389/fphys.2019.0022310.3389/fphys.2019.00223 ↗
23. 10.1016/j.bbamcr.2017.06.02010.1016/j.bbamcr.2017.06.020 ↗
24. 10.1016/S0092-8674(88)91065-310.1016/S0092-8674(88)91065-3 ↗
25. 10.1016/j.canlet.2019.01.04610.1016/j.canlet.2019.01.046 ↗
26. 10.1016/j.biopha.2017.10.15710.1016/j.biopha.2017.10.157 ↗
27. 10.1038/ncomms1328710.1038/ncomms13287 ↗
28. 10.1093/nar/gkw09310.1093/nar/gkw093 ↗
29. 10.1038/cdd.2013.11010.1038/cdd.2013.110 ↗
30. 10.1038/mt.2015.17010.1038/mt.2015.170 ↗
31. 10.1016/j.mcp.2018.06.00310.1016/j.mcp.2018.06.003 ↗
32. 10.1089/dna.2017.388610.1089/dna.2017.3886 ↗
33. 10.1089/dna.2017.382910.1089/dna.2017.3829 ↗
34. 10.1242/jcs.0038410.1242/jcs.00384 ↗
35. 10.1038/8962410.1038/89624 ↗
36. 10.1126/stke.2001.100.re1210.1126/stke.2001.100.re12 ↗